LETTERS TO THE EDITOR

Polymyositis and cyclosporin A

Sir: Polymyositis is an inflammatory disease of striated muscle of unknown cause. When it is accompanied by the characteristic skin lesions the disease is called dermatomyositis.¹ Although controlled studies have not been carried out, it seems that corticosteroids are beneficial, particularly in acute polymyositis/dermatomyositis.^{1,2} Certain patients, however, need very high doses or do not respond to this treatment. Such patients have been treated with a wide spectrum of immunosuppressive agents, alone or combined with steroids, with variable response.² Successful treatment with cyclosporin A in acute polymyositis/dermatomyositis has been reported,³⁻⁵ but long term follow up of these patients is lacking. We present a report of three patients with polymyositis/dermatomyositis,¹ in whom cyclosporin A treatment was tapered after their recovery from an acute bout of the disease.

CASE 1

A 46 year old woman presented with progressive weakness in hip and shoulder girdles, arthritis, Raynaud's phenomenon, and heliotrope rash. A diagnosis of type II dermatomyositis was established by clinical, laboratory, electromyographic, and histopathological studies. Studies to rule out neoplasia were negative. The patient started treatment with methylprednisolone (1 mg/kg/day), with partial clinical improvement. Five months later the patient's clinical status worsened and she developed Cushingoid changes. Azathioprine was added (2 mg/kg/day), without clinical improvement. This treatment was then stopped and cyclosporin A treatment was started (5 mg/kg/day). A good clinical response was obtained during the first week. Two months later she suffered a new bout related to a voluntary withdrawal of cyclosporin A treatment. Treatment was restarted and muscle strength recovered again completely. Cyclosporin A was stopped 10 months later. After remaining asymptomatic for more than 17 months the patient was readmitted because of severe dyspnoea and cervical lymphadenopathy. An interstitial pattern was noted on a chest radiogram. Six days later the patient suffered a fatal pulmonary thromboembolism. A lymph gland biopsy that had been performed some days before disclosed the presence of a metastatic adenocarcinoma.

CASE 2

A 48 year old woman presented in September 1984 with weakness in both girdles, fever, and heliotrope rash. A diagnosis of type II dermatomyositis was established by clinical, laboratory, electromyographic, and histopathological studies. Neoplasia was ruled out. Treatment with methylprednisolone (1.5 mg/kg/day) was started. Three months later, after no clinical response, the patient developed Cushingoid signs and upper gastrointestinal bleeding secondary to duodenal ulcer. Previous treatment was then stopped and treatment with cyclosporin A (7.5 mg/kg/day) was started. Fever and rash disappeared in a few days, and muscle strength recovered completely. Cyclosporin A treatment was stopped in July 1986. From that moment and so far the patient has remained asymptomatic.

CASE 3

A 53 year old woman was admitted in March 1983 to our hospital because of oedema in eyelids, hands, and malleolar regions, stiffness, Raynaud's phenomenon, progressive dyspnoea, telangiectasia, and proximal sclerosis. Oesophageal manometry showed impaired motility. Antinuclear antibodies were positive (1/6400) with a nucleolar pattern. A diagnosis of progressive systemic sclerosis was made. In May 1985 she was readmitted because of severe weakness of both girdles. Electromyographic and histopathological studies showed myositis. Corticosteroid treatment (1 mg/kg/day) was started, without clinical improvement. Treatment with cyclosporin A was then started (5 mg/kg/day), with muscle strength recovery. This treatment was stopped in January 1987. From then the patient has been asymptomatic.

Polymyositis/dermatomyositis left to its spontaneous evolution has a high mortality, estimated to be more than 60%.⁶ Most authors agree that steroids are useful in the treatment of acute forms.² Failure to respond to steroid treatment occurs in 25-50% of patients, however.⁷ In this 'steroid resistant' group other immunosuppressant treatments, including cyclosporin A, have been tried, with variable results.²⁻⁸

Cyclosporin A is a peptidic drug with immunosuppressant activity that interferes with the synthesis and release of lymphokines from the T helper subset.⁹ Some authors agree with the usefulness of cyclosporin A in the acute forms of polymyositis/dermatomyositis,³⁻⁵ but its effectiveness in chronic polymyositis is not clear. Cyclosporin A was given to all three patients because of failure or severe side effects of conventional treatment. A good correlation was found between clinical improvement and cyclosporin A administration in all the patients.

Side effects that might be attributed to cyclosporin A treatment in our patients are hirsutism and tremor in all of them, and mild hypertension with moderate impairment of renal function in patient No 1. All these abnormalities, very common in patients receiving cyclosporin A,¹⁰ were reversed after the drug was tapered off. These few cases show that cyclosporin A can be useful in patients with acute forms of polymyositis/dermatomyositis. Suppression of cyclosporin A treatment in polymyositis/dermatomyositis can produce a new bout of the disease, but probably in some patients the cyclosporin A treatment given for an indefinite period might stop the activity of the disease even after withdrawal of the treatment for many months. Thus cyclosporin A may be the treatment of choice when conventional immunosuppressant therapy fails or when adverse effects of this treatment are important. More studies are needed to corroborate these clinical observations.

J ALIJOTAS
J BARQUINERO
J ORDI
M VILARDELL
Pso Pedro III
No 58 2^a 3^a
Manresa 08240
Barcelona
Spain

- 1 Bohan A, Peter J B. Polymyositis and dermatomyositis. *N Engl J Med* 1975; 292: 344-7, 403-7.
- 2 Spiegel T M, Pearson C M. Polymyositis. In: Isselbacher K J, et al, eds. *Harrison's principles of internal medicine. Update III*. New York: McGraw-Hill, 1982: 209-22.
- 3 Zabel P, Leimenstoll A, Gross W L. Cyclosporin for acute dermatomyositis. *Lancet* 1984; ii: 343.
- 4 The H S G, Jacobs P, Houben H. Cyclosporin in

the treatment of intractable polymyositis. *Arthritis Rheum* 1985; 28: 1436-7.

- 5 Van der Meer S, Inhof J W, Borleffs J C. Cyclosporin for polymyositis. *Ann Rheum Dis* 1986; 45: 612.
- 6 Albert J, Lamberti A, Ott H, Wanthier D. Polydermatomyosite de l'adulte et conduite de son traitement. *Semaine des Hopitaux de Paris* 1983; 59: 517-22.
- 7 Henriksson K G, Sandstedt P. Polymyositis—treatment and prognosis. *Acta Neurol Scand* 1982; 65: 280-300.
- 8 Bunch T W, Worthington J W, Combs J J, Ilstrup D M, Engel A G. Azathioprine with prednisone for polymyositis. *Ann Intern Med* 1980; 92: 365-9.
- 9 Cohen D J, Loertscher R, Rubin M F, Tilney N L, Carpenter C B, Strom T B. Cyclosporin: a new immunosuppressive agent for organ transplantation. *Ann Intern Med* 1984; 101: 667-82.
- 10 Palestine A G, Nussenblatt R B, Chan C C. Side effects of systemic cyclosporin in patients not undergoing transplantation. *Am J Med* 1984; 77: 652-6.

Toxic shock syndrome associated arthropathy

Sir: We read with interest the recent paper by Foley-Nolan *et al*,¹ which states 'the only previous report of a patient with the toxic shock syndrome and associated arthritis was a 15 year old girl'.

We previously reported arthritis as a manifestation of toxic shock syndrome² and would draw this to the attention of the author and your readers.

This recalls a couplet which is apt:
When I am dead, I hope it may be said:
'His sins were scarlet, but his papers were read.'
(After Hillaire Belloc, *On His Books*.)

R D INMAN
The Toronto Hospital Arthritis Centre
399 Bathurst Street
Toronto, Ontario
Canada M5T 2S8

- 1 Foley-Nolan D, Coughlan R J, Sugrue D. Toxic shock syndrome associated arthropathy. *Staphylococcus aureus: A further triggering event in reactive arthritis?* *Ann Rheum Dis* 1989; 48: 331-2.
- 2 Gertner E, Inman R D. Aseptic arthritis in a man with toxic shock syndrome. *Arthritis Rheum* 1986; 29: 910-2.

Destructive arthropathy after successful renal transplantation

Sir: In their recent article Duncan *et al* reported two patients treated for chronic renal failure, who developed a severe erosive arthropathy at a relatively young age.¹ Case 2 had slight degenerative changes of both hands after two years of haemodialysis. Eleven years after successful renal transplantation he had developed a severe erosive arthropathy. We report here a patient with chronic renal failure who developed her first joint complaints and later a destructive arthropathy after successful renal transplantation.

A 52 year old white woman attended the outpatient clinic of the department of rheumatology in 1983 with a six month history of pain and swelling of the hands. In 1968 she developed renal failure secondary to chronic pyelonephritis. She underwent haemodialysis from 1971 to 1976 and then received a renal graft. After initial problems, for which she needed antirejection treatment on four occasions, the graft functioned well (mean creatinine clearance 86 ml/min). There was no family history of osteoarthritis or psoriasis.

On examination she had a synovitis of the interphalangeal joint of both thumbs, the proximal interphalangeal joints of the right middle finger and left ring finger, and the distal interphalangeal joint of the left index finger. All other joints were unremarkable. Radiographs of her hands showed soft tissue

swelling around the third and fourth finger on both sides. There was a slight joint space narrowing of the proximal interphalangeal joint of the right middle finger and rather extensive degenerative changes of the interphalangeal joint of both thumbs, including irregular joint space narrowing, osteophytes, and cysts (fig 1). A synovial biopsy showed an aspecific chronic inflammation. No amyloid or iron was present. Without specific treatment the complaints gradually lessened.

In 1989 she attended the outpatient clinic of the department of rheumatology again, with increasing pains in her hands. At that time she was treated with azathioprine (100 mg daily), prednisone (alternating 7.5 and 10 mg daily), and atenolol (50 mg daily). On examination there was a bony swelling of the interphalangeal joint of both thumbs and a telescopic shortening of the left ring finger and the right little finger. Furthermore, there was a tenosynovitis of musculus extensor digiti propii on the right side. Laboratory investigation showed an erythrocyte sedimentation rate of 10 mm in one hour, normal peripheral blood counts, serum calcium, and parathyroid hormone concentrations. Rheumatoid factors were negative. HLA typing: A10, A26, A29, B8, Bw72, Cw6, DR4, and DR7. Radiographs of her hands showed extensive erosive changes, predominantly in the proximal interphalangeal joints of the third and fifth digit of the left hand and the fourth digit of the right hand (fig 2).

Our patient developed a destructive arthropathy after a successful renal transplantation. The clinical and radiological picture closely resembled the changes observed in patients with psoriatic arthritis, but she did not have any skin lesions. As azathioprine and prednisone are both effective drugs for psoriasis this treatment might have concealed the disorder.² Furthermore, she may develop skin lesions in the future as some patients with

psoriatic arthritis show the first skin lesions up to 15 years after the joint complaints.³ Psoriatic arthritis is associated with (among others) HLA-Cw6 and DR7.^{4,5} HLA-DR4 has been shown to be associated with the development of erosions.⁵ All three histocompatibility antigens were present in our patient.

In their article Duncan *et al* did not discuss the radiological differential diagnostic problems of erosive osteoarthritis and psoriatic arthritis. Both are erosive polyarthritides with prominent interphalangeal joint involvement, often resulting in bony ankylosis.^{6,7} Psoriatic arthritis characteristically gives asymmetrical ill defined erosions, unaccompanied by significant osteoporosis and associated with extensive subperiosteal bone proliferation. Erosive osteoarthritis is characterised by symmetrical joint involvement, subchondral erosions, and more subtle linear periosteal bone apposition.

Our patient developed extensive erosions during a clinically quiescent period. These findings are similar to those of the long term studies on the effect of second line treatment in rheumatoid arthritis: the patients showed a clinical and haematological response, but no changes in radiological progression.^{8,9} In conclusion, the patient presented has an erosive arthropathy after successful renal transplantation, both clinically and radiologically almost indistinguishable from psoriatic arthritis.

F EGGELEMEIJER
B A C DIJKMANS
Department of Rheumatology
University Hospital Leiden
The Netherlands

- 1 Duncan I J S, Hurst N P, Disney A, Sebben R, Milazzo S C. Is chronic renal failure a risk factor for the development of erosive osteoarthritis? *Ann Rheum Dis* 1989; 48: 183-7.
- 2 Du Vivier A, Munro D D, Verbov J. Treatment of psoriasis with azathioprine. *Br Med J* 1974; i: 49-51.
- 3 Dixon A S T. 'Rheumatoid arthritis' with negative serological reaction. *Ann Rheum Dis* 1960; 19: 209-28.
- 4 Gladman D D, Anhorn K A B, Schachter R K, Mervart H. HLA antigens in psoriatic arthritis. *J Rheumatol* 1986; 13: 586-92.
- 5 McHugh N J, Laurent M R, Treadwell B L J, Tweed J M, Dagger J. Psoriatic arthritis: clinical subgroups and histocompatibility antigens. *Ann Rheum Dis* 1987; 46: 184-8.
- 6 Martel W, Stuck K J, Dworin A M, Hylland R G. Erosive osteoarthritis and psoriatic arthritis: a radiologic comparison in the hand, wrist, and foot. *AJR* 1980; 134: 125-35.
- 7 Gold R H, Basset L W, Theros E G. Radiologic comparison of erosive polyarthritides with prominent interphalangeal involvement. *Skeletal Radiol* 1982; 8: 89-97.
- 8 Iannuzzi L, Dawson N, Zein N, Kushner I. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? *N Engl J Med* 1983; 309: 1023-8.
- 9 Pullar T, Hunter J A, Capell H A. Does second-line therapy affect the radiological progression of rheumatoid arthritis? *Ann Rheum Dis* 1984; 43: 18-23.

Lack of serum antibodies to native type II collagen in leprosy

Sir: We were most interested in the finding of antibodies to native type II collagen in lepromatous leprosy reported by Choi *et al*.¹ They specifically looked at lepromatous leprosy because of the high titre antibody to *Mycobacterium leprae* and the apparent lack of joint involvement in this disease. This last presumption is incorrect as a rheumatoid-arthritis-like syndrome with nodules has been described in this disease.² We wished to confirm these findings by looking at patients with leprosy who had definite arthritis. If verified, we wondered whether there might be a cross reactivity between epitopes on *Mycobacterium leprae* and native type II collagen. This would have important implications for the possible aetiopathogenesis of rheumatoid arthritis (RA).

Serum antibodies to native type II collagen and denatured type II collagen measured by enzyme linked immunosorbent assay (ELISA)

	Antibody to (units/ml):	
	Nat II*	Denat II*
Upper limit of normal	<198	<716
Leprosy	0-85	168-1001
RA* (positive control)	1434	1616

*Nat II= native type II collagen; Denat II=denatured type II collagen; RA=rheumatoid arthritis.

We obtained serum samples, from 10 patients (nine male, one female, aged 23-60 years) with leprosy (seven lepromatous leprosy, two tuberculoid leprosy, and one borderline), all with joint involvement (both large and small joints in five, small joints only in three, and large joints only in two). Five were receiving regular treatment, three had taken intermittent treatment, and two were untreated.

Serum antibodies to native type II and denatured type II collagen were measured by enzyme linked immunosorbent assay (ELISA).³ Serum samples from 22 normal controls were used to determine an upper limit of normal as three standard deviations above the mean. A known high positive control (RA) was included. The results are shown in the table.

None of our patients had raised serum antibodies to native type II collagen, though three patients had slightly raised levels to denatured type II collagen (757, 814, and 1001 units/ml). Our results for native type II collagen therefore disagree with those of Choi *et al*, who found 11 out of 20 sera to be positive. The reason for this difference is not apparent. We do verify that antibodies to denatured type II collagen occur, though in low titre and less commonly than the 13 out of 20 sera previously reported positive. This probably reflects an antibody response to connective tissue inflammation because of cross reactivity with other denatured collagens or the binding of immune complexes. Further studies in larger series of patients with lepromatous leprosy are needed, but our negative results suggest that antibodies to native type II collagen are largely restricted to RA.

R B CLAGUE
K MORGAN
I REYNOLDS
Department of Rheumatology
Stofford Building
University of Manchester
H MISRA
Department of Rheumatology
Wythenshawe Hospital
Manchester
V MAJUMDAR
S K HAZRA
S N CHAUDHURY
Department of Leprosy
School of Tropical Medicine
Calcutta, India

Figure 1: Hand radiograph.

Figure 2: Hand radiograph.

- 1 Choi E K, Gatenby P A, McGill N W, Bateman J F, Cole W G, York J R. Autoantibodies to type II collagen: occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue diseases, and chronic inflammatory syndromes. *Ann Rheum Dis* 1988; 47: 313-22.
- 2 Karat A B A, Karat S, Job C K, Furness M A. Acute exudative arthritis in leprosy-rheumatoid-arthritis-like syndrome in association with erythema nodosum leprosum. *Br Med J* 1967; iii: 770-2.
- 3 Morgan K, Clague R B, Collins I, Ayad S, Phinn S D, Holt P J L. Incidence of antibodies to native and denatured cartilage collagen (types II, IX, and XI) and to type I collagen in rheumatoid arthritis. *Ann Rheum Dis* 1987; 46: 920-7.